PHAT · Nasdaq · CIK 0001783183

Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc.’s most recent SEC filing in our snapshot is a Form 8-K filed on Oct 26, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $175.1M and net income of -$221.2M, according to its XBRL data on EDGAR. Its EDGAR record lists 27 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$175.1M
Net income, FY2025
-$221.2M
Form 4 filings on record, past 12 months
27

Company overview

Legal name (as filed)
Phathom Pharmaceuticals, Inc.
Ticker
PHAT
SEC Central Index Key (CIK)
0001783183
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
FLORHAM PARK, NJ
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company
Position in SEC ticker list
#2822 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Phathom Pharmaceuticals, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021$0FY2022$682.0KFY2023$55.3MFY2024$175.1MFY2025
Net income
-$143.9MFY2021-$197.7MFY2022-$201.6MFY2023-$334.3MFY2024-$221.2MFY2025
PHAT annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue—$0$682.0K$55.3M$175.1M
Net income-$143.9M-$197.7M-$201.6M-$334.3M-$221.2M
Diluted EPS-$3.89-$5.05-$3.93-$5.29-$3.03
Total assets$189.4M$164.8M$413.8M$378.3M$259.1M
Cash and equivalents$183.3M$155.4M$381.4M$297.3M$130.0M

XBRL tags used: revenue = Revenues; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

PHAT latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 26, 202610-KAnnual report· period Dec 31, 2025Document · Index
Jul 30, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 26, 20268-KOther events· period Oct 26, 2026Document · Index
Apr 7, 2026DEF 14ADefinitive proxy statement· period May 19, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Phathom Pharmaceuticals, Inc., by form type:

4 ×188-K ×910-Q ×2SCHEDULE 13G ×2SCHEDULE 13G/A ×2424B5 ×2DEFA14A ×1ARS ×1DEF 14A ×1S-8 ×110-K ×1
PHAT recent filings
FiledFormWhat it isOriginal
Oct 26, 20268-KOther events· period Oct 26, 2026Document · Index
Oct 23, 20268-KOther events· period Oct 23, 2026Document · Index
Oct 8, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 6, 2026Document · Index
Sep 29, 20268-KOther events· period Sep 29, 2026Document · Index
Sep 8, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 3, 2026Document · Index
Jul 30, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Jul 30, 20268-KResults of operations· period Jul 30, 2026Document · Index
Jul 29, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Jul 20, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jul 16, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 14, 2026Document · Index
Jun 23, 20268-KOther events· period Jun 23, 2026Document · Index
May 27, 20264Statement of changes in beneficial ownership (insider trade)· period May 22, 2026Document · Index
May 21, 20264Statement of changes in beneficial ownership (insider trade)· period May 19, 2026Document · Index
May 21, 20264Statement of changes in beneficial ownership (insider trade)· period May 19, 2026Document · Index
May 21, 20264Statement of changes in beneficial ownership (insider trade)· period May 19, 2026Document · Index
May 21, 20264Statement of changes in beneficial ownership (insider trade)· period May 19, 2026Document · Index
May 21, 20264Statement of changes in beneficial ownership (insider trade)· period May 19, 2026Document · Index
May 21, 20264Statement of changes in beneficial ownership (insider trade)· period May 19, 2026Document · Index
May 21, 20264Statement of changes in beneficial ownership (insider trade)· period May 19, 2026Document · Index
May 21, 20268-KShareholder vote results· period May 19, 2026Document · Index
Apr 30, 202610-QQuarterly report· period Mar 31, 2026Document · Index
Apr 30, 20268-KResults of operations· period Apr 30, 2026Document · Index
Apr 7, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 7, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 7, 2026DEF 14ADefinitive proxy statement· period May 19, 2026Document · Index
Mar 27, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Mar 12, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Mar 11, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 10, 2026Document · Index
Mar 3, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 27, 2026Document · Index
Feb 26, 202610-KAnnual report· period Dec 31, 2025Document · Index
Feb 26, 20268-KResults of operations· period Feb 26, 2026Document · Index
Feb 12, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 10, 2026Document · Index
Feb 12, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 10, 2026Document · Index
Jan 27, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 23, 2026Document · Index
Jan 27, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jan 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 21, 2026Document · Index
Jan 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 13, 2026Document · Index
Jan 8, 20268-KOther events· period Jan 7, 2026Document · Index
Jan 8, 2026424B5424B5Document · Index
Jan 7, 2026424B5424B5Document · Index

Insider filing activity

27 Form 4 filings appear in Phathom Pharmaceuticals, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in New Jersey

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001783183 and XBRL company facts. Phathom Pharmaceuticals, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.